Emergency Medicine
Infectious Disease
Public Health, Policy, and Training

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties


The New England Journal of Medicine: Search Results in Dermatology
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Dermatology. NEJM ( is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Evaluation and Management of Lower-Extremity Ulcers
01/01/70 - Lower-extremity ulcers are very common, with an estimated prevalence of 1 to 2% among U.S. adults, and they have a major effect on public health. Lower-extremity ulcers are divided into two groups ? leg ulcers and foot ulcers ? because of differences in causes, pathogenesis, and treatment. Even…

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
01/01/70 - Psoriatic arthritis is a chronic, systemic inflammatory arthritis that occurs in 6 to 42% of patients with psoriasis, affecting the peripheral joints, tendons, ligaments, and the axial skeleton. Current treatment guidelines for psoriatic arthritis recommend conventional synthetic disease-modifying…

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
01/01/70 - Psoriatic arthritis is a chronic inflammatory disease that is characterized by peripheral arthritis, enthesitis, dactylitis, axial disease, and skin manifestations. Depending on the clinical manifestations of the disease, recommended treatments, in addition to topical and systemic treatments for…

JAK Inhibitors Taking on Psoriatic Arthritis
01/01/70 - Psoriasis is a chronic inflammatory skin disease that affects 2 to 4% of the population. Inflammatory arthritis develops in approximately 30% of patients with psoriasis and can have a major effect on activities of daily living and quality of life. Peripheral joint involvement in patients with…

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
01/01/70 - The treatment of advanced melanoma has improved considerably over the past 6 years. Ipilimumab, an anti?cytotoxic T-lymphocyte?associated antigen 4 (CTLA-4) fully human monoclonal antibody, was the first systemic therapy to show prolonged overall survival among patients with advanced melanoma in…

"Acrobatic" Lice
01/01/70 - Figure 1.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
01/01/70 - Ipilimumab (Yervoy, Bristol-Myers Squibb), a human IgG1 monoclonal antibody against cytotoxic T-lymphocyte antigen 4, and nivolumab (Opdivo, Bristol-Myers Squibb), a human IgG4 monoclonal antibody against programmed death 1 (PD-1), are approved for monotherapy and combination therapy in several…

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
01/01/70 - The incidence of cutaneous melanoma has continued to increase in recent years. For early-stage melanoma, surgical resection is the standard treatment and is associated with an excellent long-term prognosis, with 5-year survival rates of 98% for stage I disease and 90% for stage II disease. However,…

Sturge?Weber Syndrome
01/01/70 - Figure 1.

Case 26-2017: A 63-Year-Old Woman with Fever, Hypotension, and Hypoxemia
01/01/70 - Presentation of Case. Dr. Robert H. Goldstein (Medicine): A 63-year-old woman was admitted to the intensive care unit (ICU) of this hospital because of fever, hypotension, and hypoxemia. Five months before the current admission, weakness of the proximal muscles of the arms and dyspnea on exertion…

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins